Oscar Health: The Industry Is Having A Cold But 2026 Looks To Be Much Better

Oscar Health Inc. (OSCR) has grown revenue significantly to an estimated $12 billion in 2025, yet carries a $4.3 billion market capitalization, reflecting depressed industry valuations. After being profitable in 2024, the company reported Q2 2025 losses and anticipates a full-year loss due to elevated medical loss rates, but projects a return to profitability in 2026 driven by substantial, industry-wide premium rate increases and its scalable technology platform. With new leadership and a strong balance sheet, the stock presents a compelling risk-reward profile, despite potential headwinds from evolving ACA regulations and high short interest.

Analysis

Oscar Health (OSCR) presents a significant valuation disconnect, with a market capitalization of $4.3 billion against guided 2025 revenues of $12 billion. This discrepancy is contextualized by a severe, industry-wide downturn in health insurance stocks. The company anticipates a net loss for 2025, driven by a sharp increase in its medical loss ratio to 91.1% in Q2 2025, indicating inadequate premium pricing for the current year's medical cost trends. However, management projects a return to profitability in 2026, contingent on substantial, industry-wide premium rate increases for which it has already filed in states covering 98% of its membership. This potential earnings recovery is supported by a strong balance sheet, including an estimated $579 million in excess statutory capital, and improving operational leverage, with SG&A as a percentage of revenue guided to decrease to approximately 17.1-17.6% for 2025. Key risks remain concentrated in its reliance on the ACA marketplace, which faces legislative uncertainty regarding the potential expiration of premium tax credits after 2025. The stock's high short interest of 24.2% reflects significant market skepticism but also introduces the potential for a short squeeze should the company execute on its 2026 profitability target.

Key Decisions for Investors

• Investors with a higher risk appetite could consider the stock a compelling turnaround play, as a successful return to profitability in 2026 driven by premium hikes could trigger a significant re-rating from its current deep value multiple of approximately 0.36x forward sales.
• Closely monitor legislative developments concerning the extension of ACA premium tax credits, as a failure to extend them beyond 2025 represents the single largest headwind to Oscar's membership growth and revenue outlook.
• The exceptionally high short interest should be viewed as a key technical factor; while it signals strong bearish sentiment, any positive surprises in execution or a favorable regulatory outcome could fuel a rapid short squeeze.
• Consider OSCR as a high-beta investment on a potential recovery in the health insurance sector; its high growth profile and depressed valuation could lead to outperformance relative to larger peers if sector-wide sentiment improves.